Publications
Probity Medical Research has compiled journals, articles and presentations for your personal review. Please use the search features below to find an article.
If you would like to request an article for personal review please complete the registration form. These publications are for personal use only and cannot be distributed.
Already granted access to an article?
If you cannot find the article you are looking for please contact Probity Medical Research.
Journals, Articles and Presentations
Articles by Publication Year
2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009
2016 Sep; 20(5): 375-431. Epub 2016 Jul 15.
Phase 3 Trials of Ixekizumab in Moderate-to-severe Plaque Psoriasis
2016 Jul 28; 375(4): 3345-56. Epub 2016 Jun 8.
Daylight-Mediated Photodynamic Therapy for Actinic Keratosis
2016 Jul/Aug; 8(4): 265-8.
Effectiveness of Sequential Use of Biologics in the Treatment of Moderate to Severe Psoriasis in Real World Canadian Academic Clinical Practice: A Cohort Study
2016 Jan; 74(1):176-7.
Treatment with Tildrakizumab, an Anti–IL-23p19 Monoclonal Antibody, Improves Health-Related Quality of Life in Patients with Chronic Plaque Psoriasis
Presented at EULAR 2016, London, England, 8-11 June 2016.
A Prospective Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis
2016 Aug; 175(2): 273-86. Epub 2016 Jun 23.
Safety and Tolerability of Apremilast Up to 182 weeks: Pooled Analyses From Phase 3 Clinical Trials
Presented at the CDA 91st Annual Meeting, Saskatoon, Saskatchewan, June 2016.
52-Week Efficacy and Safety of Apremilast and Switch From Etanercept in Patients With Moderate to Severe Psoriasis: Results From the LIBERATE Study
Presented at the Annual European Congress of Rheumatology EULAR 2016, London, England, June 8-11, 2016.
Clinician Training in Motivational Communication Skills: The Impact of Derm Connect Canada (Phase 1)
Presented at the 91st CDA Annual Conference, Saskatoon, Saskatchewan, June 22-25, 2016.
LIBERATE Trial: Sustained Efficacy of Apremilast in Patients With Nail and Scalp Psoriasis Who Continued on Apremilast or Switched From Etanercept
Presented at the 91st CDA Annual Conference, Saskatoon, Saskatchewan, June 22-25, 2016.
About PMR | Investigators | Experience | Locations | News | Publications | Privacy Policy | Contact | Sitemap |
Copyright 2014 Probity Medical Research Inc. All Rights Reserved.